Schedule 13G ownership disclosure

ArriVent Biopharma Inc

Common Stock · CUSIP: 04272N102

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • INFINITUM ASSET MANAGEMENT, LLC

    Shares: 4,123,923.00 · Class: 9.9%

  • Infinitum Partners GP, LLC

    Shares: 4,123,923.00 · Class: 9.9%

  • Infinitum Cayman Master, Ltd.

    Shares: 4,123,923.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002058093-26-000004
Form type
SCHEDULE 13G/A
Filer
ArriVent BioPharma, Inc.
CIK
CIK 1868279
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub